Butyric acid diminishes angiotensin II-induced hypertension in mice [95], and some SCFAs are known to have ligands that can potentially be engineered as therapeutic targets for hypertension (e.g., GPR41, GPR43, GPR109a in mice and SCFA receptors such as Olf78/OR51E2 in human) [96]. This evidence concerns the gene HCAR2 and hypertensive disorder.